NeurologyLive® Year in Review 2025: Roundtable Roundup – Reviewing this Year’s Launched Programming
Published: | Updated:
Discover key conversations from leaders in neurology covering a range of different clinically relevant topics.
NeurologyLive® Staff
Advertisement
Articles by NeurologyLive® Staff
Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
As part of NeurologyLive®'s Year in Review, we've compiled some notable trials that began in 2025.
FDA Approves Inebilizumab for Myasthenia Gravis, Phase 3 PREVAiLS Study Launched, Tolebrutinib Fails Phase 3 PERSEUS Study
Published: | Updated:
Neurology News Network for the week ending December 20, 2025. [WATCH TIME: 4 minutes]
NDA Accepted for Narcolepsy Oxybate TRN-257, Gene Therapy ETX101 Early Promise in Dravet, Bexicaserin's Impact on Developmental Encephalopathies
Published: | Updated:
Neurology News Network for the week ending December 13, 2025. [WATCH TIME: 4 minutes]
FDA Approves Intrathecal Version of Zolgensma, Ozempic Falls Short in EVOKE Trials, Asundexian Meets End Point in Stroke Prevention Trial
Published: | Updated:
Neurology News Network for the week ending November 29, 2025. [WATCH TIME: 4 minutes]
FDA Makes Label Change to Elevidys, ALS Prevalence to Increase by 2040, CNM-Au8 NDA Submitted
Published: | Updated:
Neurology News Network for the week ending November 22, 2025. [WATCH TIME: 4 minutes]
BBP-418 Success in LGMD, Alixorexton Improves Narcolepsy Symptoms, Fenebrutinib Meets Phase 3 End Points
Published: | Updated:
Neurology News Network for the week ending November 15, 2025. [WATCH TIME: 4 minutes]
Neflamapimod Phase 3 Trial in DLB, Troriluzole Gets CRL for SCA, Periodontal Disease and Stroke Risk
Published: | Updated:
Neurology News Network for the week ending November 8, 2025. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending November 1, 2025. [WATCH TIME: 3 minutes]
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
Published: | Updated:
Neurology News Network for the week ending October 25, 2025. [WATCH TIME: 4 minutes]
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
Published: | Updated:
Neurology News Network. for the week ending October 18, 2025. [WATCH TIME: 4 minutes]
36-Month Data on Bemdaneprocel, Ravulizimab Shines in CHAMPION-NMOSD Trial, FDA Fast Tracks Anti-MBTR Tau Antibody
Published: | Updated:
Neurology News Network. for the week ending October 11, 2025. [WATCH TIME: 4 minutes]
Updated NMOSD Diagnostic Criteria, Tavapadon NDA Submitted, MIL-62 Shows Promising Treatment Effects in NMOSD
Published: | Updated:
Neurology News Network. for the week ending October 4, 2025. [WATCH TIME: 4 minutes]
High Dose Nusinersen, Apitegromab Receive CRLs, Tolebrutinib PDUFA Pushed Back
Published: | Updated:
Neurology News Network. for the week ending September 27, 2025. [WATCH TIME: 4 minutes]
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
Published: | Updated:
Neurology News Network. for the week ending September 13, 2025. [WATCH TIME: 4 minutes]
Efgartigimod Meets End Point in Seronegative Myasthenia Gravis Study, Cemdisiran Submission for MG Coming Soon, Phase 3 Studies of IncobotulinumtoxinA Begin
Published: | Updated:
Neurology News Network. for the week ending August 30, 2025. [WATCH TIME: 4 minutes]
Vatiquinone Recieves CRL, RAINBOWFISH Study Published in NEJM, Hearing Aids Show Protective Effects Against Dementia
Published: | Updated:
Neurology News Network. for the week ending August 23, 2025. [WATCH TIME: 4 minutes]
Vormatrigine Reduces Seizures in Phase 2 RADIANT Study, Postpartum Depression in MS Women, Ianalumab Produces Significant Phase 3 Data in Sjögren’s disease
Published: | Updated:
Neurology News Network. for the week ending August 16, 2025. [WATCH TIME: 4 minutes]
Elecsys Blood Test Gains EU Approval, FDA Expands Fremanezumab Indication Into Pediatrics, VX-993 Fails Phase 2 Pain Trial
Published: | Updated:
Neurology News Network. for the week ending August 9, 2025. [WATCH TIME: 4 minutes]
IHL-42X Performs in Phase 2 RePOSA Study, ATH434 Eyes Phase 3 Multiple System Atrophy Trial, 4-Year Data on Lecanemab Unveiled
Published: | Updated:
Neurology News Network. for the week ending August 2, 2025. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Gefurulimab Positive Phase 3 Data Released, PoNS Device Eyes Stroke Indication, AD109 Performs in Phase 3 LunAIRo Trial
Published: | Updated:
Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Sleep Agent Oveporexton Meets End Points in Phase 3 Studies, XPro Shows Mixed Phase 2 Data, Ultraprocessed Food Consumption Linked to Parkinson's Features
Published: | Updated:
Neurology News Network. for the week ending July 19, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 18, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
FDA Approves Updated Donanemab Labeling, BLA Accepted for Tividenofusp Alfa, Nipocalimab Outperforms FcRn Blockers
Published: | Updated:
Neurology News Network. for the week ending July 12, 2025. [WATCH TIME: 4 minutes]
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy
2
What Salanersen's FDA Breakthrough Designation Means for Spinal Muscular Atrophy
3
Understanding the Clinical Value of the INCAT Disability Score
4
Alzheimer Agent PMN310 Shows No ARIA-E in Six-Month Interim Analysis of Phase 1b AD Trial
5